Tillkännagivande • May 19
CannaPharmaRX, Inc. announced delayed 10-Q filing On 05/18/2026, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Tillkännagivande • Jan 14
Cannapharmarx, Inc. Announces Resignation of Director Rick Orman, Effective January 8, 2026 CannaPharmaRX, Inc. announced that on January 8, 2026, Rick Orman informed the Board of Directors of his resignation as a member of the Board effective immediately. Mr. Orman's resignation from the Board did not indicate it was the result of any dispute or disagreement with the Company or the Board on any matter relating to the operations, policies, or practices of the Company. Tillkännagivande • Aug 22
Cannapharmarx, Inc. Announces Revenue Guidance for Third Quarter 2025 CannaPharmaRX, Inc. announced revenue guidance for third quarter 2025. The company projects revenues of approximately CAD 1,050,000, with the anticipation of additional shipments before the end of September. This forecast may vary slightly depending on fluctuations in the Euro-to-Canadian Dollar exchange rate. Tillkännagivande • May 17
CannaPharmaRX, Inc. announced delayed 10-Q filing On 05/16/2025, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Tillkännagivande • Apr 02
CannaPharmaRX, Inc. announced delayed annual 10-K filing On 04/01/2025, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Tillkännagivande • Jun 06
CannaPharmaRX, Inc. Announces CEO Changes CannaPharmaRx, Inc. announced that the company has appointed a new CEO. Dean Medwid succeeds Domenic Colvin, who will stay with the company providing leadership and vision. Mr. Medwid assumed CEO duties earlier this month and will guide the company through its rapid growth phase. Mr. Medwid is a dynamic senior operations executive with more than thirty years of experience in both public and private markets with a focus on scalable process engineering, brand development and strategic partnerships. He has been recognized with numerous business awards and accolades, including Profit 100's Top 100 in Canada, five years in a row while a partner in Seattle's Best Coffee, additionally was a awarded the recognition of being one of Vancouver's Top 40 Under 40. Mr. Medwid recently exited his prior company in the retail cannabis sector and looks forward to bringing that background to the company as they target new revenue opportunities this year. His strengths include driving growth through the expansion of market segments and geography resulting in multi-year growth. Mr. Medwid also has extensive experience creating internal processes for departmental budgets, technology standards and human resource policies resulting in an engaged workforce as well as developing corporate governance aligned to generally accepted accounting principles. Mr. Medwid has a demonstrated history of increasing corporate performance through the management of process design, customer relationships, strategic planning along with a focused initiative of data-driven change management and utilized these skills as President of other successful publicly traded companies with operations in multiple countries. Tillkännagivande • May 17
CannaPharmaRX, Inc. announced delayed 10-Q filing On 05/15/2024, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Tillkännagivande • Mar 28
CannaPharmaRX, Inc. announced delayed annual 10-K filing On 03/27/2024, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Tillkännagivande • Nov 15
CannaPharmaRX, Inc. announced delayed 10-Q filing On 11/14/2023, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Tillkännagivande • Oct 15
CannaPharmaRX, Inc. Announces Executive Changes Effective October 13, 2023, John Cassels is being replaced as the Chief Financial Officer (“CFO”) of CannPharmaRX, Inc. effective June 1, 2023. There was no disagreement between and Mr. Cassels on any matter related to operations, policies or practices that led to Mr. Cassels’s replacement as CFO. Effective October 13, 2023, Board of Directors has determined to appoint Oliver Foeste as Chief Financial Officer. Mr. Foeste has consented to such appointment. Mr. Foeste is the founder and Managing Partner of Invictus Accounting Group LLP and has significant executive, director, finance, and public company compliance experience across a number of industry sectors including cannabis and nutraceuticals. Prior to Invictus, Mr. Foeste was in senior finance and accounting roles at TSX, TSXV, and NYSE listed issuers, and earned his CPA at Deloitte and a boutique tax advisory firm. Tillkännagivande • Aug 26
CannaPharmaRx Expands Board of Directors CannaPharmaRX, Inc. announced that it has expanded its board of directors from three seats to five. The board deemed this expansion was in the best interest of the corporation as it coincides with an expansion of operations. The following person(s) were elected to the Board to fill the newly created directorships until the next annual meeting of stockholders of the corporation: Mr. Anthony Panek, age 38, is a corporate mergers and acquisitions attorney and venture capital investor with expertise in capital raising formation and growing businesses. He has worked with private equity and venture capital funds to allocate capital to emerging growth companies and works with emerging growth companies, both public and private, to raise capital and acquire assets and corporate talent. He has been an investor in many emerging growth companies and private funds investing in similar companies. He works with companies from a business and legal perspective to navigate and manage growth challenges facing emerging growth companies and helping companies complying with their SEC reporting obligations. He completed the Venture Capital Certificate Program at Startup@Berkeley Law. Mr. Panek was selected to serve on the Company's Board based upon his experience as an attorney and venture capital and private equity investor helping emerging companies raise capital, comply with SEC reporting and governance requirements, and his work with other cannabis companies. Mr. Adam Mindle, age 52, is a transactional attorney with extensive experience in structuring, negotiating and documenting sophisticated joint ventures, secured financing and mergers and acquisitions related to real estate, healthcare and technology companies. In 2010, Mr. Mindle co-founded Greystone Law Group LLP. Prior to co-founding Greystone Law Group LLP, Mr. Mindle was a partner in the Los Angeles officer of Orrick, Herrington & Sutcliffe LLP. Mr. Mindle is a veteran authority on real estate, finance and corporate transactions having represented real estate developers, private equity funds, pension funds, REITs, public and private companies and institutional lenders in connection with the acquisition and disposition of real estate assets, secured financing and joint ventures. During his three-decade career, Mr. Mindle has guided numerous start-up companies, mature organizations, pension funds, REITs and other public and private companies through a myriad of sophisticated transactions valued in billions of dollars. The third and final board position will look to be filled in the near future. Mark Branson has chosen to step down from his current position on the Board. Tillkännagivande • Jun 24
CannaPharmaRX, Inc. Announces CEO Changes CannaPharmaRx, Inc. announced that the company has appointed a new CEO. Dean Medwid succeeds Domenic Colvin, who will stay with the company providing leadership and vision. Mr. Medwid assumed CEO duties earlier this month and will guide the company through its rapid growth phase. Mr. Medwid is a dynamic senior operations executive with more than thirty years of experience in both public and private markets with a focus on scalable process engineering, brand development and strategic partnerships. He has been recognized with numerous business awards and accolades, including Profit 100's Top 100 in Canada, five years in a row while a partner in Seattle's Best Coffee, additionally was a awarded the recognition of being one of Vancouver's Top 40 Under 40. Mr. Medwid recently exited his prior company in the retail cannabis sector and looks forward to bringing that background to the company as they target new revenue opportunities this year. His strengths include driving growth through the expansion of market segments and geography resulting in multi-year growth. Mr. Medwid also has extensive experience creating internal processes for departmental budgets, technology standards and human resource policies resulting in an engaged workforce as well as developing corporate governance aligned to generally accepted accounting principles. Mr. Medwid has a demonstrated history of increasing corporate performance through the management of process design, customer relationships, strategic planning along with a focused initiative of data-driven change management and utilized these skills as President of other successful publicly traded companies with operations in multiple countries. Tillkännagivande • Jan 12
CannaPharmaRx Receives Canada Revenue Agency (CRA) License As Final Step to Bringing Facility Into Production With Annual Revenues of Over $30 Million Expected CannaPharmaRx, Inc. announced that it has received its CRA license. A company can start producing cannabis products after receiving licensing from both the CRA and Health Canada. CannaPharmaRx can now begin business activities relating to the production and sale of cannabis. The license is valid for up to two years. CannaPharmaRx is now authorized to grow cannabis and sell wholesale to other licensed producers throughout Canada. The CRA oversees regulation of cannabis products including the production, possession, removal, sale and distribution of cannabis as well as impose proper excise duties and taxes on cannabis products. Now that both licenses are approved the company anticipates completing the first harvest during the current quarter with estimated annual revenue over $30 million. Tillkännagivande • Nov 15
CannaPharmaRX, Inc. announced delayed 10-Q filing On 11/14/2022, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Tillkännagivande • Aug 13
CannaPharmaRX, Inc. announced delayed 10-Q filing On 08/12/2022, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Tillkännagivande • May 17
CannaPharmaRX, Inc. announced delayed 10-Q filing On 05/16/2022, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Tillkännagivande • Apr 01
CannaPharmaRX, Inc. announced delayed annual 10-K filing On 03/31/2022, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Tillkännagivande • Feb 11
CannaPharmaRX, Inc. (OTCPK:CPMD) signed a letter of intent to acquire Operating Cannabis Facility Located in Braman, Oklahoma. CannaPharmaRX, Inc. (OTCPK:CPMD) signed a letter of intent to acquire Operating Cannabis Facility Located in Braman, Oklahoma on February 10, 2022. The purchase will be completed via a secured note and will include the transfer of licenses. The transaction is expected to close prior to March 31, 2022. Tillkännagivande • Jun 09
An unknown buyer entered in an agreement to acquire Hanover, Ontario Facility for CAD 2 million. An unknown buyer entered in an agreement to acquire Hanover, Ontario Facility for CAD 2 million on June 8, 2021. The proceeds of the sale will provide working capital, allowing the facility to become production ready in a short period of time. Senior management unanimously agreed a sale was most beneficial for the company and its stakeholders. The deal is expected to close on June 30, 2021. Tillkännagivande • Apr 03
CannaPharmaRX, Inc. announced delayed annual 10-K filing On 04/01/2021, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Tillkännagivande • Jan 29
CannaPharmaRX, Inc. (OTCPK:CPMD) entered into a definitive agreement to acquire Assets and Facilities Located in Saskatoon, Saskatchewan for CAD 12 million. CannaPharmaRX, Inc. (OTCPK:CPMD) entered into a definitive agreement to acquire Assets and Facilities Located in Saskatoon, Saskatchewan for CAD 12 million on January 18, 2021. The purchase price is subject to adjustments. CannaPharmaRX will pay the purchase price for the facility which means the sum of: (i) CAD 12 million and (ii) the CannaPharmaRX share of the option purchase price, not including goods and services tax. The payment schedule for the purchase price will be a deposit of CAD 0.1 million will be paid on execution of the agreement, CAD 5.9 million, plus 50% of the share of the option purchase price, plus the deposit, together with any goods and services tax thereon, subject to adjustments as hereinafter described, shall be paid to the seller’s solicitor on or before the closing date; then CAD 3 million plus the remaining 50% of the share of the option purchase price, together with any goods and services tax thereon, shall be paid within 3 Business Days of the Cultivation Licensing Approval Date; and then CAD 3 million together with any goods and services tax thereon, shall be paid within 3 Business Days of the Processing Licensing Approval Date. The transaction is subject to satisfaction of due diligence, board approval and certain closing conditions. The transaction is expected to close in February 2021. Tillkännagivande • Jan 13
CannaPharmaRX, Inc. (OTCPK:CPMD) entered into a Purchase and Sale Agreement to acquire assets and facilities in Cremona AB for CAD 12 million. CannaPharmaRX, Inc. (OTCPK:CPMD) entered into a Purchase and Sale Agreement to acquire assets and facilities in Cremona AB for CAD 12 million on January 7, 2021. The company will pay the “Purchase Price” for the facility which means the sum of: (i) CAD 12 million and (ii) the Purchaser’s Share of the Option Purchase Price, not including Goods and Services Tax. The payment schedule for the Purchase Price will be a deposit of CAD 0.1 million paid on execution of the PSA, the CAD 5.9 million, plus 50% of the Purchaser’s Share of the Option Purchase Price, plus the deposit, together with any Goods and Services Tax thereon, subject to adjustments as hereinafter described, shall be paid to the Seller’s solicitor on or before the closing date; then CAD 3 million plus the remaining 50% of the Purchaser’s Share of the Option Purchase Price, together with any Goods and Services Tax thereon, shall be paid within 3 Business Days of the Cultivation Licensing Approval Date; and then CAD 3 million, together with any Goods and Services Tax thereon, shall be paid within 3 Business Days of the Processing Licensing Approval Date. The transaction is subject to certain closing conditions and is scheduled to close in February 2021. Tillkännagivande • Aug 19
CannaPharmaRX, Inc. announced that it has received $3 million in funding from Triton Funds LLC CannaPharmaRX, Inc. (OTCPK:CPMD) announced that it has received $3,000,000 in a round of funding from new investor Triton Funds LLC on August 18, 2020. Tillkännagivande • Aug 15
CannaPharmaRX, Inc. announced delayed 10-Q filing On 08/14/2020, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Tillkännagivande • Jul 07
CannaPharmaRX, Inc. (OTCPK:CPMD) entered into a purchase agreement to acquire Cannabis Production Facility in Cathedral City, California from Bristol Capital Advisors, LLC for $10 million. CannaPharmaRX, Inc. (OTCPK:CPMD) entered into a purchase agreement to acquire Cannabis Production Facility in Cathedral City, California from Bristol Capital Advisors, LLC for $10 million on June 24, 2020. The acquisition is anticipated to close during the next 45 days, subject to CannapharmaRx receiving appropriate funding. Bennett J. Yankowitz of Shumaker Mallory LLP acted as legal advisor to Bristol, Joshua D. Brinen of Brinen & Associates, LLC acted as legal advisor to CannaPharmaRX. 
